Linezolid

Drug Profile

Linezolid

Alternative Names: PNU 100766; U 100766; Zyvox; Zyvoxam; Zyvoxid

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Acetamides; Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vancomycin-resistant enterococcal infections; Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Diabetic foot ulcer; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Nosocomial pneumonia; Skin and soft tissue infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Jun 2015 Pfizer terminates a phase III trial in Optic nerve disorders in USA, Italy and Sweden (NCT00359632)
  • 01 Jan 2014 Seoul National University Hospital initiates a phase II trial in Tuberculosis (pulmonary) in South Korea (NCT01994460)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top